PS
VRTX icon

Principal Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Principal Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.97M Sell
5,982
-596
-9% -$264K 0.04% 412
2026
Q1 		$2.94M Buy
6,578
+259
+4% +$121K 0.04% 371
2025
Q4 		$2.86M Sell
6,319
-518
-8% -$223K 0.04% 359
2025
Q3 		$2.68M Buy
6,837
+237
+4% +$99K 0.04% 367
2025
Q2 		$2.94M Buy
6,600
+1,137
+21% +$524K 0.06% 309
2025
Q1 		$2.2M Hold
5,463
– – 0.05% 330
2024
Q4 		$2.2M Buy
5,463
+1,164
+27% +$540K 0.05% 327
2024
Q3 		$2M Buy
4,299
+226
+6% +$109K 0.05% 348
2024
Q2 		$1.91M Buy
4,073
+1,127
+38% +$489K 0.05% 312
2024
Q1 		$1.23M Buy
2,946
+582
+25% +$246K 0.04% 397
2023
Q4 		$962K Buy
+2,364
New +$873K 0.04% 422

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Principal Securities's VRTX Position: Q2 2026 in Review

Principal Securities reduced its Vertex Pharmaceuticals (VRTX) stake by 9.1% in Q2 2026, selling an estimated $264K and leaving 5,982 shares worth $2.97M. The position accounts for 0.04% of the portfolio, ranked #412.

Principal Securities first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Principal Securities held 5,982 shares of Vertex Pharmaceuticals worth $2.97M as of Q2 2026.
  • Principal Securities sold 596 Vertex Pharmaceuticals shares in Q2 2026, an estimated $264K.
  • Vertex Pharmaceuticals made up 0.04% of Principal Securities's portfolio in Q2 2026, its #412 holding.
  • Principal Securities first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.